| Stereochemistry | RACEMIC |
| Molecular Formula | C14H20N2O2 |
| Molecular Weight | 248.3208 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)COC1=C(C=CC=C1)C#N
InChI
InChIKey=VCVQSRCYSKKPBA-UHFFFAOYSA-N
InChI=1S/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3
| Molecular Formula | C14H20N2O2 |
| Molecular Weight | 248.3208 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Bunitrolol is a beta-adrenergic antagonist that can be used for treatment of coronary heart disease. It improves cardiac performance after beta-blockade in patients with coronary artery disease. Bunitrolol was found to have a greater beta 1 than beta 2 adrenergic activity and a weak alpha 1 blocking action.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Bunitrolol 10 mg administered to patients with coronary artery disease
Route of Administration:
Intravenous
For assessments of pharmacological activities of bunitrolol the guinea pig trachea, left and right atria and aorta, and the rat aorta were used. Dose-response curves were obtained in the absence or presence of bunitrolol of the following concentrations: trachea, left and right atria 10(-8) M, guinea pig aorta 10(-4) M; rat aorta, 3x10(-6) M.
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 3 of 3 entries
